SUBSCRIBE
SUBSCRIBE

Celldex Therapeutics

NEWS
Drug Development
Stock Dives as Celldex Cuts 20% of Staff After Phase II Breast Cancer Failure
On April 16, Celldex Therapeutics reported that its Phase IIb trial of glembatumumab vedotin (glemba) failed in a trial of metastatic triple-negative breast cancer. Now the company has filed with the U.S. Securities and Exchange Commission (SEC) that it is cutting about 20 percent of staff.
April 25, 2018
 · 
3 min read
 · 
Mark Terry
Deals
Celldex’s Biggest Failure in 2016
December 16, 2016
 · 
1 min read
Proteostasis and Roche Diagnostics Ink Huge Space in New Boston Hub
Business
Little Celldex is Sitting on Plenty of Cash and is Ready to Go Shopping
November 8, 2016
 · 
2 min read
Tiny KalVista Explodes on $760 Million Deal With Drug Giant Merck & Co.
Business
Celldex Takes Out Kolltan Pharma in $235 Million Deal
November 2, 2016
 · 
2 min read
ESMO 2016 Takeaways: Don't Miss Celldex, Exelixis and Tesaro
Drug Development
ESMO 2016 Takeaways: Don’t Miss Celldex, Exelixis and Tesaro
October 12, 2016
 · 
3 min read
Wall Street's Top Biotech Analyst Loves These 2 Life Science Stocks
Biotech Bay
Celldex Who? 2 Not-as-Risky Stocks That Shot Up in the Past Year
October 4, 2016
 · 
2 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Deals
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
June 2, 2016
 · 
2 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Drug Development
Celldex Stock Chokes as Brain Cancer Trial Halted
March 7, 2016
 · 
3 min read
ASCO15: Bristol Myers Cancer Drug Combo Shrinks 60% of Melanomas, As Oncology Roars
Drug Development
ASCO15: Hope Rises As Celldex’s Brain Cancer Vaccine Helps Patients Live Longer
June 1, 2015
 · 
4 min read
IN THE PRESS
Press Releases
Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints
September 22, 2026
 · 
10 min read
Press Releases
Celldex Reports Second Quarter Financial Results and Provides Corporate Update
August 7, 2026
 · 
11 min read
Press Releases
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis
July 22, 2026
 · 
8 min read
Press Releases
Celldex Announces Planned Transition of Chief Financial Officer
July 16, 2026
 · 
4 min read
Press Releases
Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting
June 15, 2026
 · 
8 min read
Press Releases
Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting
June 15, 2026
 · 
9 min read
Press Releases
Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress
June 11, 2026
 · 
6 min read
Press Releases
Celldex Reports First Quarter Financial Results and Provides Corporate Update
May 8, 2026
 · 
11 min read
Press Releases
Celldex to Present at Upcoming April 2026 Investor Conference
April 14, 2026
 · 
1 min read
Press Releases
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 7, 2026
 · 
2 min read
JOBS